Search
Displaying 581–590 of 623 for “retinal diseases”
-
ARVO 2021 Highlight: Update on Clinical Trial of jCyte’s Cellular Therapy for RP
Research NewsCellular treatment provided significant improvements in visual acuity for subpopulation of patients with better vision
-
Beacon Stories
American Banker dubbed her as “the sharpest mind analyzing banking policy today – maybe ever.”
-
Managing Your Mindset, Embracing Your Voice
WellnessCharity’s recent rapid decline in vision due to RP and her daughter’s diagnosis with RP has caused her to open up about her vision loss journey. After getting involved with the Foundation, Charity now feels like she has a voice to help others in the visually impaired community.
-
Genentech’s Faricimab Performs Well in Phase 3 Clinical Trials for Wet AMD
Research NewsCompany will seek marketing approval for the emerging therapy
-
REGENXBIO’s Wet AMD Gene Therapy Moving into Phase 3 Trials
Research NewsIn a Phase ½ clinical trial, the emerging treatment reduced the burden of regular anti-VEGF injections
-
The Foundation’s best-in-class genetic testing program enables any eye care professional in the US to order no-cost genetic testing through the Foundation’s My Retina Tracker Program and genetic counseling for patients clinically diagnosed with an IRD.
-
AGTC Planning Phase 2/3 Clinical Trial for XLRP Gene Therapy
Research NewsThe company is also expanding its Phase ½ trial for the emerging treatment
-
Beacon Stories
Tracy was the fourth generation of his family to receive the diagnosis of retinitis pigmentosa, but he never let that stop him from dreaming big. Tracy has worked at NASA’s Johnson Space Center for over 36 years, making significant contributions over the many years.
-
Genentech’s Port Delivery System for Wet AMD Meets Primary Endpoint in Phase 3 Clinical Trial
Research NewsTiny implant provides continual delivery of anti-VEGF treatment for six months
-
Positive Interim Clinical Trial Results for Adverum’s Wet AMD Gene Therapy
Research NewsThe gene therapy is designed to reduce the treatment burden for patients
